Rescue Treatment for Migraine Headache in Emergency Department Part 1: Diagnosis, General Management, and Role of Dopamine Antagonists and NSAIDs
Article Sidebar
Published:
Feb 20, 2014
Keywords:
treatment for migraine headache, migraine headache in emergency
Main Article Content
Abstract
Migraine is a common recurrent neurological disorder with a high impact and is debilitating. Approximately 14.7% of the global population has migraine (an estimated 6% in men and up to 18% in women).1 A recent report ranked migraine headache as the third most common disease in the world (behind dental caries and tension type headache).2 On the basis of migraine attack disability alone, migraine was ranked seventh highest among specific causes of disability globally (responsible for 2.9% of all years of life lost to disability).
Article Details
How to Cite
1.
Vongvaivanich K. Rescue Treatment for Migraine Headache in Emergency Department Part 1: Diagnosis, General Management, and Role of Dopamine Antagonists and NSAIDs. BKK Med J [Internet]. 2014 Feb. 20 [cited 2024 Nov. 23];7(1):86. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/219632
Issue
Section
Case Report
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
2. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia 2013;33:289-90.
3. Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36.
4. Diamond M, Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 2005;118:18S-27S.
5. Gupta MX, Silberstein SD, Young WB, et al. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache 2007;47: 1125-33.
6. Friedman BW, Bijur PE, Lipton RB. Standardizing emer- gency department-based migraine research: an analysis of commonly used clinical trial outcome measures. Acad Emerg Med 2010;17:72-9.
7. Dodick DW. Clinical clues and clinical rules: primary versus secondary headache. Adv. Stud Med 2003;3:550-5.
8. Headache Classification Committee of the International Headache Society (IHS).The International Classification of Headache Disorders, 3rd edition (beta version). Cepha- lalgia 2013;33:629-808.
9. Lipton RB, Dodick D, Sadovsky R, et al. A self-adminis- tered screener for migraine in primary care: the ID Migraine™ validation study. Neurology 2003;61:375-82.
10. Mostardini C, d’Agostino VC, Dugoni DE, et al. A pos- sible role of ID-Migraine in the emergency department: study of an emergency department out-patient population. Cephalalgia 2009;29:1326-30.
11. Cousins G, Hijazze S, Van de Laar FA, et al. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache 2011;51:1140-8.
12. Silberstein SD. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 1995; 35:387-96.
13. Silberstein S. Gastrointestinal manifestations of migraine: meeting the treatment challenges. Headache 2013;53:1-3
14. Logan P, Lewis D. Chlorpromazine in migraine. Emerg Med J 2007;24:297-300.
15. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
16. Barbanti P, Fofi L, Aurilia C, et al. Dopaminergic symp-toms in migraine. Neurol Sci 2013;34:S67-70.
17. Ghosh J, Pradhan S, Mittal B. Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromolecular Med 2013;15:61-73.
18. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 2009; 125:265-79.
19. Castillo J, Martinez F, Suarez C, et al. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenyl-acetic acid levels in migraine patients. Cephalalgia 1996;16:56-61.
20. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache 2012;52:292-306.
21. Bigal ME. Phenothiazines in migraine treatment. Curr Pain Headache Rep 2010;14:253-5.
22. Marmura J. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14:27-35.
23. Kelly AM, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. Headache 2009;49:1324-32.
24. Bigal ME, Bordini CA, Speciali JG. Intravenous chlor- promazine in the emergency department treatment of migraine: A randomized controlled trial. J Emerg Med 2002;23:141-8.
25. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhy- drinate in migraine headache. Ann Emerg Med 1989;18 360-5.:
26. Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990;19:1079-82.
27. Kelly AM, Ardagh M, Curry C, et al. Intravenous chlor- promazine vs. intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997;14:209-11.
28. Colman I, Brown MD, Innes GD, et al. Parenteral meto- clopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004;329:1369-73.
29. Tek DS, McClellan DS, Olshaker JS, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 1990;19:1083-7.
30. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-6.
31. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg PsyChiatry 1980;43: 369-71.
32. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5.
33. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med 1996;14:262-4.
34. Cameron JD, Lane PL, Speechley M. Intravenous chlor- promazine vs. intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2:597-602.
35. Cete Y, Dora B, Ertan C, et al. A randomized perspective placebo-controlled study of intravenous magnesium sulfate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2004;25:199-204.
36. Friedman BW, Corbo J, Lipton RB, et al. A trial of meto- clopramide vs. sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463-8.
37. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011;57:475-82.
38. Honkaniemi J, Liimatainen S, Rainesalo S, et al. Halo- peridol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 2006; 46:781-7.
39. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53: 167-78.
40. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997;53: 139-88.
41. Strom BL, Berlin lA, Kinman JL, et al. Parenteral ketoro- lac and risk of gastrointestinal and operative site bleeding: a post marketing surveillance study. JAMA 1996;275: 376-82.
42. DuBose lr TO, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344:515-8.
43. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-222.
44. Taggart E, Doran S, Kokotillo A, et al. Ketorolac in the treatment of acute migraine: a systematic review. Head- ache 2013;53:277-87.
45. Colman I, Rothney A, Wright S, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
46. Meredith JT, Wait S, Brewer KL. A prospective double- blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003;21:173-5.
47. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5:573-6.
48. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
49. Schuh-Hofer S, Tayefeh M, Reuter U, et al. Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Headache 2006;46:276-85.
50. Müller T, Lohse L. Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. Clin Neuropharmacol 2011;34:206-9.
51. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-22.
52. Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
53. Levin M. Opioids in Headache. Headache 2014;54:12-21.
54. Buse DC, Pearlman SH, Reed ML, et al. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012;52:18-36.
55. Bigal ME, Lipton RB. Excessive opioid use and the devel- opment of chronic migraine. Pain 2009;142:179-82.
56. Bigal ME, Serrano D, Buse D, et al. Acute migraine medi- cations and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157-68.
57. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical consider- ations. Clin J Pain 2008;24:479-96.
58. Tepper SJ. Opioids should not be used in migraine. Head- ache 2012;52:30-4.
59. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache 2009;49:395-403.
60. Friedman BW, Hochberg ML, Esses D, et al. Recurrence of primary headache disorders after emergency depart- ment discharge: Frequency and predictors of poor pain and functional outcomes. Ann Emerg Med 2008;52: 696-704.
61. Friedman BW, Kapoor A, Friedman MS, et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 2008;52:705-13.
62. Tepper DE, Kelley NE. Rescue therapy for acute migraine, part 3: Opioids, NSAIDs, steroids, and post- discharge medications. Headache 2012;52:467-82.
63. Finocchi C, Viani E. Opioids can be useful in the treat-ment of headache. Neurol Sci 2013;34:S119-24.
64. Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: A single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther 2007;29:1441-7.
65. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective, randomized, double-blind study. J Headache Pain 2005;6: 143-8.
2. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia 2013;33:289-90.
3. Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36.
4. Diamond M, Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 2005;118:18S-27S.
5. Gupta MX, Silberstein SD, Young WB, et al. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache 2007;47: 1125-33.
6. Friedman BW, Bijur PE, Lipton RB. Standardizing emer- gency department-based migraine research: an analysis of commonly used clinical trial outcome measures. Acad Emerg Med 2010;17:72-9.
7. Dodick DW. Clinical clues and clinical rules: primary versus secondary headache. Adv. Stud Med 2003;3:550-5.
8. Headache Classification Committee of the International Headache Society (IHS).The International Classification of Headache Disorders, 3rd edition (beta version). Cepha- lalgia 2013;33:629-808.
9. Lipton RB, Dodick D, Sadovsky R, et al. A self-adminis- tered screener for migraine in primary care: the ID Migraine™ validation study. Neurology 2003;61:375-82.
10. Mostardini C, d’Agostino VC, Dugoni DE, et al. A pos- sible role of ID-Migraine in the emergency department: study of an emergency department out-patient population. Cephalalgia 2009;29:1326-30.
11. Cousins G, Hijazze S, Van de Laar FA, et al. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache 2011;51:1140-8.
12. Silberstein SD. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 1995; 35:387-96.
13. Silberstein S. Gastrointestinal manifestations of migraine: meeting the treatment challenges. Headache 2013;53:1-3
14. Logan P, Lewis D. Chlorpromazine in migraine. Emerg Med J 2007;24:297-300.
15. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
16. Barbanti P, Fofi L, Aurilia C, et al. Dopaminergic symp-toms in migraine. Neurol Sci 2013;34:S67-70.
17. Ghosh J, Pradhan S, Mittal B. Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromolecular Med 2013;15:61-73.
18. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 2009; 125:265-79.
19. Castillo J, Martinez F, Suarez C, et al. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenyl-acetic acid levels in migraine patients. Cephalalgia 1996;16:56-61.
20. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache 2012;52:292-306.
21. Bigal ME. Phenothiazines in migraine treatment. Curr Pain Headache Rep 2010;14:253-5.
22. Marmura J. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14:27-35.
23. Kelly AM, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. Headache 2009;49:1324-32.
24. Bigal ME, Bordini CA, Speciali JG. Intravenous chlor- promazine in the emergency department treatment of migraine: A randomized controlled trial. J Emerg Med 2002;23:141-8.
25. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhy- drinate in migraine headache. Ann Emerg Med 1989;18 360-5.:
26. Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990;19:1079-82.
27. Kelly AM, Ardagh M, Curry C, et al. Intravenous chlor- promazine vs. intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997;14:209-11.
28. Colman I, Brown MD, Innes GD, et al. Parenteral meto- clopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004;329:1369-73.
29. Tek DS, McClellan DS, Olshaker JS, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 1990;19:1083-7.
30. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-6.
31. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg PsyChiatry 1980;43: 369-71.
32. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5.
33. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med 1996;14:262-4.
34. Cameron JD, Lane PL, Speechley M. Intravenous chlor- promazine vs. intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2:597-602.
35. Cete Y, Dora B, Ertan C, et al. A randomized perspective placebo-controlled study of intravenous magnesium sulfate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2004;25:199-204.
36. Friedman BW, Corbo J, Lipton RB, et al. A trial of meto- clopramide vs. sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463-8.
37. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011;57:475-82.
38. Honkaniemi J, Liimatainen S, Rainesalo S, et al. Halo- peridol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 2006; 46:781-7.
39. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53: 167-78.
40. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997;53: 139-88.
41. Strom BL, Berlin lA, Kinman JL, et al. Parenteral ketoro- lac and risk of gastrointestinal and operative site bleeding: a post marketing surveillance study. JAMA 1996;275: 376-82.
42. DuBose lr TO, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344:515-8.
43. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-222.
44. Taggart E, Doran S, Kokotillo A, et al. Ketorolac in the treatment of acute migraine: a systematic review. Head- ache 2013;53:277-87.
45. Colman I, Rothney A, Wright S, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
46. Meredith JT, Wait S, Brewer KL. A prospective double- blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003;21:173-5.
47. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5:573-6.
48. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
49. Schuh-Hofer S, Tayefeh M, Reuter U, et al. Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Headache 2006;46:276-85.
50. Müller T, Lohse L. Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. Clin Neuropharmacol 2011;34:206-9.
51. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-22.
52. Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
53. Levin M. Opioids in Headache. Headache 2014;54:12-21.
54. Buse DC, Pearlman SH, Reed ML, et al. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012;52:18-36.
55. Bigal ME, Lipton RB. Excessive opioid use and the devel- opment of chronic migraine. Pain 2009;142:179-82.
56. Bigal ME, Serrano D, Buse D, et al. Acute migraine medi- cations and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157-68.
57. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical consider- ations. Clin J Pain 2008;24:479-96.
58. Tepper SJ. Opioids should not be used in migraine. Head- ache 2012;52:30-4.
59. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache 2009;49:395-403.
60. Friedman BW, Hochberg ML, Esses D, et al. Recurrence of primary headache disorders after emergency depart- ment discharge: Frequency and predictors of poor pain and functional outcomes. Ann Emerg Med 2008;52: 696-704.
61. Friedman BW, Kapoor A, Friedman MS, et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 2008;52:705-13.
62. Tepper DE, Kelley NE. Rescue therapy for acute migraine, part 3: Opioids, NSAIDs, steroids, and post- discharge medications. Headache 2012;52:467-82.
63. Finocchi C, Viani E. Opioids can be useful in the treat-ment of headache. Neurol Sci 2013;34:S119-24.
64. Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: A single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther 2007;29:1441-7.
65. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective, randomized, double-blind study. J Headache Pain 2005;6: 143-8.